2. DEVELOPMENT OF NEW DRUGS IN THE POSTGENOMIC ERA |
"Hit" and "lead" compounds. Choice of pathology and biological target. Validation of a target. "Lead" compounds and development of new drugs. In silico chemistry. Screening. Compound optimization. Other therapeutic strategies. |
3. BIOPHARMACEUTICAL TECHNOLOGIES AND PROCESSES IN DRUG DEVELOPMENT |
Data mining, molecular cloning and characterization. Gene isolation. Protein expression systems. Molecular optimization to increase protein expression. Rational design. Examples: Sandostatin, Norvir, Enbrel. Drug development process. Clinical trials. |
4. SOURCES OF BIOPHARMACEUTICALS AND FINAL PRODUCT ANALYSIS |
Biopharmaceutical production systems. E.coli as a source of recombinant therapeutic proteins. Expression of recombinant proteins in animal cell culture systems. Additional production systems: Yeasts, fungi, transgenic animals, mosses and insects. Protein-based contaminants. Elimination of altered forms of the protein of interest. Detection of protein-based impurities. Capillary electrophoresis. HPLC. Mass spectrometry. Immunological approaches for the detection of contaminants. Endotoxins and other pyrogenic pollutants. |
6. VACCINES |
Vaccines as specific immunoactivating drugs based on antigen processing. Identification of the type of vaccines by their origin and composition. Synthetic, recombinant, anti-idiotype vaccines. The immunology of adjuvants. Vaccine applications: infectious diseases, autoimmune diseases and cancer. Perspectives on the development of new vaccines |
8. MONOCLONAL ANTIBODIES AND IMMUNOTOXINS |
Immunoglobulins and antisera as passive specific immunoactivating drugs. Distinguish immunoglobulin from antiserum. Place monoclonal antibodies, humanized monoclonal antibodies, and immunotoxins in this context. Pharmacologically characterize these products. Identify the products of this type currently marketed. |